Urolithin A Evidence Match Report
A product-to-evidence map distinguishing Mitopure human evidence, generic ingredient-level evidence and complex finished formulas.
The problem with borrowed evidence
A generic Urolithin A product can reasonably discuss ingredient-level human research, but it should not automatically inherit Mitopure-specific certification, manufacturing or finished-product positioning. Multi-active formulas create an additional gap because human evidence on one ingredient does not prove the exact combination.
Evidence-match comparison
| Product | Ingredient identity | Finished-product evidence | Evidence Match | Complexity |
|---|---|---|---|---|
| Timeline — Mitopure Softgels | Mitopure branded Urolithin A | Yes - Mitopure human trials | 10/10 | 1/5 |
| Timeline — Mitopure Powder | Mitopure branded Urolithin A | Yes - Mitopure human trials | 10/10 | 1/5 |
| Timeline — Mitopure Gummies | Mitopure branded Urolithin A | Yes - Mitopure human trials | 10/10 | 1/5 |
| Timeline — Mitopure Softgels Sample | Mitopure branded Urolithin A | Yes - Mitopure human trials | 10/10 | 1/5 |
| Timeline — Mitopure Powder Sample | Mitopure branded Urolithin A | Yes - Mitopure human trials | 10/10 | 1/5 |
| Timeline — Mitopure Gummies Sample | Mitopure branded Urolithin A | Yes - Mitopure human trials | 10/10 | 1/5 |
| Naturecan — Urolithin A | Urolithin A | Not captured for exact finished formula | 8/10 | 1/5 |
| Double Wood — Urolithin A | Urolithin A | Not captured for exact finished formula | 8/10 | 1/5 |
| DoNotAge — Urolithin A - 500 mg/day option | Urolithin A | Not captured for exact finished formula | 8/10 | 1/5 |
| DoNotAge — Urolithin A - 1,000 mg/day option | Urolithin A | Not captured for exact finished formula | 8/10 | 1/5 |
| Nature's Fusions — Nutri Urolithin A | Urolithin A | Not captured for exact finished formula | 8/10 | 1/5 |
| Bonerge — StanYouth Urolithin A Raw Ingredient | StanYouth branded Urolithin A >99% purity | Ingredient research / supplier clinical programs | 8/10 | 1/5 |
| Urolithin A+ — Urolithin A 1200 mg | Urolithin A | Not captured for exact finished formula | 6/10 | 1/5 |
| Codeage — Liposomal Urolithin A | Generic Urolithin A | Not captured for exact formula | 6/10 | 4/5 |
| ProHealth Longevity — Full Spectrum Urolithin A | StanYouth branded Urolithin A | Not captured for exact finished formula | 6/10 | 4/5 |
| Renue By Science — Urolithin A+ | Urolithin A | Not captured for exact finished formula | 4/10 | 2/5 |
Why Mitopure scores differently
Timeline's consumer formats use the branded Mitopure ingredient that appears in the company's human clinical program. That is a materially different evidence relationship from a generic 500 mg capsule that references the same Urolithin A literature but has not itself been studied.
Why Evidence Match exists
Urolithin A products often cite the same human literature even when the finished products are materially different.
Mitopure's direct evidence relationship
Timeline's core products use the branded Mitopure ingredient that is directly tied to the company's human clinical program.
Generic ingredient evidence
Generic Urolithin A can reasonably be discussed using ingredient-level human evidence, but the finished product should not automatically inherit Mitopure-specific certifications or product claims.
Multi-active formulas
When Urolithin A is combined with resveratrol, betaine, CoQ10, or precursor extracts, evidence on one ingredient does not prove the exact finished combination.
Why dose still matters
A product closer to studied dose ranges may map more cleanly to the literature, but matching a dose alone does not establish equivalence.
Why formulation still matters
Ingredient identity, delivery format, co-ingredients, and manufacturing can affect how confidently a commercial item maps to the evidence.
How to use the score
Evidence Match should be read alongside testing, value, and formula complexity.
What the score cannot prove
It does not predict an individual's health response and is not a substitute for product-specific clinical trials.
Update trigger 1
For Urolithin A Evidence Match Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 2
For Urolithin A Evidence Match Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 3
For Urolithin A Evidence Match Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 4
For Urolithin A Evidence Match Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 5
For Urolithin A Evidence Match Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 6
For Urolithin A Evidence Match Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 7
For Urolithin A Evidence Match Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 8
For Urolithin A Evidence Match Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 9
For Urolithin A Evidence Match Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 10
For Urolithin A Evidence Match Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.